Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication

od Ueno, Takayuki, Saji, Shigehira, Masuda, Norikazu, Iwata, Hiroji, Kuroi, Katsumasa, Sato, Nobuaki, Takei, Hiroyuki, Yamamoto, Yutaka, Ohno, Shinji, Yamashita, Hiroko, Hisamatsu, Kazufumi, Aogi, Kenjiro, Sasano, Hironobu, Toi, Masakazu
izdano v ESMO Open (2019)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial

od Ueno, Takayuki, Saji, Shigehira, Masuda, Norikazu, Kuroi, Katsumasa, Sato, Nobuaki, Takei, Hiroyuki, Yamamoto, Yutaka, Ohno, Shinji, Yamashita, Hiroko, Hisamatsu, Kazufumi, Aogi, Kenjiro, Iwata, Hiroji, Yamanaka, Takeharu, Sasano, Hironobu, Toi, Masakazu
izdano v ESMO Open (2018)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy

od Ueno, Takayuki, Saji, Shigehira, Sugimoto, Masahiro, Masuda, Norikazu, Kuroi, Katsumasa, Sato, Nobuaki, Takei, Hiroyuki, Yamamoto, Yutaka, Ohno, Shinji, Yamashita, Hiroko, Hisamatsu, Kazufumi, Aogi, Kenjiro, Iwata, Hiroji, Imoto, Shigeru, Sasano, Hironobu, Toi, Masakazu
izdano v BMC Cancer (2016)